India's first COVID-19 vaccine, COVAXIN, by Bharat Biotech gets DCGI nod for human clinical trials

The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month.

Press Trust of India June 30, 2020 17:53:08 IST
India's first COVID-19 vaccine, COVAXIN, by Bharat Biotech gets DCGI nod for human clinical trials

Hyderabad: The country's 'first' indigenous COVID-19 vaccine COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India, the company said on Monday.

The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month.

The collaboration with Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) was instrumental in the development of the vaccine, the company said in a release.

Indias first COVID19 vaccine COVAXIN by Bharat Biotech gets DCGI nod for human clinical trials

A new visualisation of the COVID-19 virus. Fusion Medical Animation/Unsplash

The indigenous and inactivated vaccine has been developed at Bharat Biotechs BSL-3 (Bio-Safety Level 3) high containment facility located in the Genome Valley, a release said.

The Drug Controller General of India CDSCO (The Central Drugs Standard Control Organisation), Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020, the release said.

Chairman and Managing Director of the company Dr. Krishna Ella said: We are proud to announce COVAXIN, Indias first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine.

"The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform," he said.

Expedited through the national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses, the released added.

Besides Bharat Biotech, at least five other Indian companies are working on a vaccine for the deadly coronavirus while similar efforts are underway in different countries.
.

Updated Date:

also read

As world waits for COVID-19 vaccine, India must use time to build robust immunisation plan, delivery system for last-mile reach
India

As world waits for COVID-19 vaccine, India must use time to build robust immunisation plan, delivery system for last-mile reach

Right from selecting the strategy for delivery of COVID-19 vaccine to recruiting a large volunteer staff, every tool must be analysed from the perspective of India’s unique public health system and its capabilities

Coronavirus LIVE Updates: Centre postpones JEE, NEET to September due to COVID-19 pandemic; Pakistan foreign minister tests positive
India

Coronavirus LIVE Updates: Centre postpones JEE, NEET to September due to COVID-19 pandemic; Pakistan foreign minister tests positive

Coronavirus LIVE Updates: Union HRD minister Ramesh Pokhriyal on Friday announced that the JEE and NEET exams have been postponed to September in view of the coronavirus pandemic.

COVID-19 'vaccine nationalism' could block vulnerable populations from access to protection
science

COVID-19 'vaccine nationalism' could block vulnerable populations from access to protection

The most immediate effect of vaccine nationalism is that it further disadvantages countries with fewer resources and bargaining power.